ClinicalTrials.gg
CompletedNCT00835666Updated Aug 19, 2024Results posted

Finasteride 5 mg Tablets Under Fasting Conditions

A Phase 1 interventional study of Finasteride 5 mg tablets and PROSCAR® in Healthy, sponsored by Teva Pharmaceuticals USA. Completed at 1 site in United States. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-19.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

The objective of this study is to compare the relative bioavailability of finasteride 5 mg tablets (manufactured and distributed by TEVA Pharmaceuticals USA) with that of PROSCAR® 5 mg tablets (Merck) in healthy, adult, non-smoking, male subjects under fasting conditions.

Read the detailed description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA bioequivalence statistical methods

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalence
  • Healthy Subjects
03

In context

Lead sponsor

Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All subjects selected for this study will be male non-smokers at least 18 years of age. Subjects will have a (body mass index) of 30 or less.
  • Each subject shall be given a general physical examination within 28 days of initiation of the study. Such examination includes, but is not limited to, blood pressure, general observations, and history.

Adequate blood and urine samples should be obtained within 28 days before beginning of the first period and at the end of the trial for clinical laboratory measurements.

Clinical laboratory measurements will include the following:

  • Hematology: , hematocrit, red blood cell count, count, white blood cell count (with differential).
  • Clinical Chemistry: creatinine, BUN, glucose, /AST, SGPT/ALT, , and alkaline phosphatase.
  • Urine Analysis: pH, specific gravity, protein, glucose, ketones, bilirubin, occult blood, and cells.
  • Screen: pre-study
  • , C Screen: pre-study
  • Drugs of Abuse Screen: pre-study and at each check-in Subjects will be selected if all above are normal. of all participating subjects will be recorded before initiation of the study and filed with each subject's case report forms.

Exclusion criteria

Exclusion Criteria:

  • Subjects with a history of chronic alcohol consumption (during past 2 years), drug addiction, or serious gastrointestinal, renal, hepatic or cardiovascular disease, tuberculosis, epilepsy, asthma (during past 5 years), diabetes, psychosis or glaucoma will not be eligible for this study.
  • Subjects whose clinical laboratory test values are greater than 20% outside the normal range on retesting, the subject will not be significant.
  • Subjects who have a history of allergic responses to the class of drug being tested should be excluded from the study.
  • All subjects will have urine samples assayed for the presence of drugs of abuse as part of the clinical laboratory screening procedures and at each study period check-in. subjects found to have urin concentrations of any of the tested drugs will not be allowed to participate.
  • Subjects should not have donated blood and/or plasma for at least thirty (30) days prior to the first dosing of the study.
  • Subjects who have taken any drug within thirty (30) days prior to the first dosing of the study will not be allowed to participate.
  • Subjects who do not tolerate venipuncture will not be allowed to participate.
  • Subjects who use tobacco in any form will not be eligible to participate in the study. Three months abstinence is require.
  • Females will not be eligible to participate in the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Finasteride

    Finasteride 5 mg Tablet (test) dosed in first period followed by Proscar® 5 mg Tablet (reference) dosed in second period

    Drug: Finasteride 5 mg tablets

  • Active comparator
    Proscar®

    Proscar® 5 mg Tablet (reference) dosed in first period followed by Finasteride 5 mg Tablet (test) dosed in second period

    Drug: PROSCAR®

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax - Maximum Observed Concentration

    Bioequivalence based on Cmax

    Time frame: Blood samples collected over 36 hour period

  2. AUCinf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)

    Bioequivalence based on AUCinf

    Time frame: Blood samples collected over 36 hour period

  3. AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)

    Bioequivalence based on AUC0-t

    Time frame: Blood samples collected over 36 hour period

07

Results

Posted Aug 4, 2009

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneFinasteride (Test) FirstProscar® (Reference) First
Started1616
Completed1616
Not completed00
Washout
Participant flow — Washout
MilestoneFinasteride (Test) FirstProscar® (Reference) First
Started1616
Completed1416
Not completed20
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject10
Second Intervention
Participant flow — Second Intervention
MilestoneFinasteride (Test) FirstProscar® (Reference) First
Started1416
Completed1416
Not completed00

Outcome measures

PrimaryCmax - Maximum Observed Concentration

Bioequivalence based on Cmax

Time frame:
Blood samples collected over 36 hour period
Reported as:
Mean · ng/mL
Cmax - Maximum Observed Concentration
ng/mLFinasterideProscar®
Cmax - Maximum Observed Concentration35.550 ± 10.17035.393 ± 8.147
Statistical analysis
  • Finasteride vs Proscar® · Geometric test/ref ratio x 100: 98.5 · 90% CI 92.6 to 105Bioequivalence is established when 90% Confidence Interval falls within 80-125.
PrimaryAUCinf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)

Bioequivalence based on AUCinf

Time frame:
Blood samples collected over 36 hour period
Reported as:
Mean · ng*h/mL
AUCinf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)
ng*h/mLFinasterideProscar®
AUCinf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)252.848 ± 97.525256.783 ± 94.167
Statistical analysis
  • Finasteride vs Proscar® · Geometric test/ref ratio x 100: 98.2 · 90% CI 94.7 to 102Bioequivalence is established when 90% Confidence Interval falls within 80-125.
PrimaryAUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)

Bioequivalence based on AUC0-t

Time frame:
Blood samples collected over 36 hour period
Reported as:
Mean · ng*h/mL
AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)
ng*h/mLFinasterideProscar®
AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)247.327 ± 90.563250.822 ± 87.883
Statistical analysis
  • Finasteride vs Proscar® · Geometric test/ref ratio x 100: 98.4 · 90% CI 94.9 to 102Bioequivalence is established when 90% Confidence Interval falls within 80-125.

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Finasteride (Test) FirstProscar® (Reference) FirstTotal
<=18 years000
Between 18 and 65 years161632
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Finasteride (Test) FirstProscar® (Reference) FirstTotal
Female000
Male161632
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Finasteride (Test) FirstProscar® (Reference) FirstTotal
Caucasian415
Black91120
Hispanic246
Asian101
Region of Enrollment
Region of Enrollment(participants)Finasteride (Test) FirstProscar® (Reference) FirstTotal
United States161632
08

Study locations

1 site
  • Novum Pharmaceutical Research Services
    Houston, Texas 77042, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2002, a primary completion of Jun 2002 and a completion of Jun 2002. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 7 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2009
First posted
Feb 4, 2009
Start
Jun 2002
Primary completionActual
Jun 2002
CompletionActual
Jun 2002
Results first posted
Aug 4, 2009
Last update
Aug 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00835666
First posted
Feb 4, 2009
Start date
Jun 2002
Primary completion
Jun 2002
Completion
Jun 2002
Results posted
Aug 4, 2009
Last update
Aug 19, 2024

Study contacts

So Ran Hong, M.D.
principal investigator · Novum Pharmaceutical Research Services

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finasteride

Start the discussion